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Ja Kyung Kim1, Kwan Sik Lee1, Hye Young Chang2, Woon Kyu Lee3 and Jung Il Lee1*Abstract
Background: Kruppel-like-factor (KLF) 10 is identified as transforming growth factor (TGF) β inducible early gene and is
reported to suppress lipogenic genes. Although previous studies report that TGFβ plays an important role in progression
of nonalcoholic steatohepatitis (NASH) by regulating liver fibrosis, the association of KLF10 and NASH has never been
explored. Thus we evaluated expressions and changes of KLF10 in diet induced NASH and in NASH which was alleviated
by ursodeoxycholic acid (UDCA). We also assessed KLF10 in quiescent and activated hepatic stellate cells (HSCs).
Methods: C57BL/6 mice were given high fat, sucrose diet (HFSD) at least for 12 weeks up to 48 weeks and sacrificed
at 12, 24 and 48 weeks thereafter. In other groups, either standard diet (SD) or HFSD was given for 24 weeks at which
point mice fed with HFSD were divided into two groups, and were given either UDCA in combination with HFSD or
vehicle with HFSD. Mice under SD were given vehicle. HSCs were isolated from C57BL/6 mice in order to evaluated
KLF10 expression in activated HSCs.
Results: The mice were found to acquire liver steatosis and inflammation starting from week 12 of HFSD feeding,
although significant liver fibrosis was noticed by week 24. Increased TGFβ and collagen α1(I) (Col1α(I)) expression was
also apparent from week 24. However, expression of KLF10 mRNA started to increase from week 12, earlier than TGFβ
gene. Up-regulation of KLF10 was accompanied by suppressed carbohydrate response element-binding protein (ChREBP)
that is known to be protective against insulin resistance. The mice fed with HFSD and UDCA had decreased Colα(I)
mRNA that was coincided with reduced TGFβ and KLF10 expression. Expression of ChREBP was also recovered by UDCA
administration. Enhanced KLF10 was noticed in activated HSCs when quiescent cell showed minimal expression.
Conclusions: Our study demonstrated that KLF10 expression was significantly increased in diet induced NASH and
collagen producing activated HSCs. We also noticed that this up-regulation of KLF10 was accompanied by increased
TGFβ signaling genes and suppressed ChREBP expression. These observations suggest possible association of KLF10
and NASH progression.Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most
prevalent chronic liver disease worldwide, ranging from
simple steatosis to steatohepatitis [1-3]. Unlike simple
steatosis, nonalcoholic steatohepatitis (NASH) is charac-
terized by hepatocellular injury with inflammation and
fibrosis that can progress to liver cirrhosis [4]. The* Correspondence: mdflorence@yuhs.ac
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most important prognostic factor [5-7].
Studies on the intriguing mechanism of liver fibrosis
identify transforming growth factor (TGF) β as a key
regulator of fibrosis [8-11]. However, being a multifunc-
tional cytokine which regulates cell survival, differentiation,
migration as well as extracellular matrix production
[12,13], targeting TGFβ itself in treating liver fibrosis
may accompany detrimental adverse effects. Studies on
the signaling of TGFβ reveal that once it binds to a
receptor which is then phosphorylated, subsequent intra-
cellular signaling pathway including Smad proteins would
activate [14]. In addition, TGFβ can induce immediate. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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factors (KLF) that would work as effector proteins [15,16].
KLF10, which is initially identified from osteoblastic
cell population [17], is known to be regulated by TGFβ/
Smad pathway. KLF10 may induce transcription of Smad2
and repress Smad7 [18-20]. It exerts its function as modu-
lating differentiation markers, suppressing proliferation
and inducing apoptosis of cells [18,21,22]. A recent study
reports that KLF10 can also suppress lipogenic genes and
that glucose stimulation induces KLF10 mRNA expres-
sion, suggesting the possible role of KLF10 on glucose and
lipid metabolism [23], two important pathways in relation
to nonalcoholic fatty liver disease.
Regarding glucose and lipid metabolism, carbohydrate
response element-binding protein (ChREBP) is known to
induce the expression of lipogenic and glycolytic genes
in response to the glucose stimulation [24,25]. Interest-
ingly, overexpression of ChREBP in mice fed with high
fat diet showed improved insulin resistance despite
the greater hepatic steatosis [26]. On the other hands,
ChREBP overexpression induces KLF10 mRNA expres-
sion in rat hepatocytes whereas KLF10 overexpression
partially suppressed ChREBP target genes [27].
KLF10 and its association with NASH have never been
studied. Here, we used diet which was high in fat and
sucrose to induce NASH and evaluated the expression
of KLF10 in the liver. We also evaluated the change of
KLF10 when diet induced NASH was alleviated after
giving ursodeoxycholic acid (UDCA). Since our obser-
vations suggested that KLF10 expression increased with
progression of NASH fibrosis and repressed as fibrosis
regressed, in vitro study using primarily cultured hepatic
stellate cells (HSCs), key players of liver fibrosis, was done.
Extracellular matrix (ECM) producing activated HSCs
showed increased KLF10 expression when compared
with that of quiescent HSCs. We additionally identified
that expression of ChREBP was suppressed in NASH
and KLF10 expression was inversely coincided with
ChREBP in the liver.
Materials and methods
Animals and experimental design
The animal experimental procedures and protocols were
approved by the Institutional Animal Care and Use
Committee (IACUC) of Gangnam Severance Hospital,
Yonsei University College of Medicine (Permit Number:
0173). The study was carried out in accordance with the
recommendation and restrictions of IACUC.
C57BL/6 male mice (8 weeks of age) were obtained
from the Central Lab Animal (Seoul, Korea) and housed
with a 12-h light-dark cycle. Zeitgeber time zero (ZT0)
referred to the time of lights on. Mice were fed with
either a standard chow (standard diet, SD) or a diet high
in saturated fat, cholesterol and sucrose, termed as highfat and sucrose diet (HFSD). HFSD, purchase from Pico-
lab (Bethlehem, PA), was consisted of 15% anhydrous
milkfat, 1.0% cholesterol, and 50% sucrose. SD or HFSD
was given at least for 12 weeks up to 48 weeks and the
mice were sacrificed at 12, 24, or 48 weeks after the
feeding. In other groups of mice, either SD or HFSD was
given for 24 weeks at which point the mice fed with
HFSD were divided into two groups. For mice under
HFSD, one group was fed with HFSD in combination
with 20 mg/kg UDCA diluted in 0.78% Tween-80 which
was administered orally through sonde for 24 weeks and
the other group of mice was given 0.78% Tween-80 with
HFSD. For mice under SD, 0.78% Tween-80 was also
given for 24 weeks. These groups of mice were sacrificed
and the liver harvested at 24 weeks after the feeding of
the experimental agents with either HFSD or SD. All the
mice were sacrificed at ZT8 and a portion of fresh liver
tissue was fixed in 10% buffered formalin, with the
remaining tissue snap-frozen in liquid nitrogen and
stored at -80°C. Blood samples were collected after anes-
thetized by cardiac puncture, and stored at -80°C.
Histology
Sections of liver tissue specimens, fixed in 10% formalin
and embedded in paraffin wax, were stained with H&E
and Sirus red for histological examination. A blinded
investigator evaluated the slides for fatty change, inflam-
mation, existence of hepatocyte ballooning, and fibrosis as
described in previous studies with minor modifications
[28-30]. Degree of steatosis was scored as the percentage
of hepatocytes containing macrovesicular fat (grade 0: no
steatosis, grade 1: <25%, grade 2: 26-50%, grade 3: 51-75%,
grade 4: 76-100%). Inflammation was histologically quan-
tified by counting inflammatory foci in 20 consecutive
high-power fields (X40 objective) (average histological
grade, grade 0: no foci, grade 1: <2 foci per high-power
field, grade 2: ≥2 foci per high-power field). The individual
scores of steatosis, inflammation and hepatocyte bal-
looning were added to produce an overall score, namely
‘NAFLD Activity Score’ (NAS) as previously suggested
[30]. Fibrosis scores were as follows: 1, pericellular and
perivenular fibrosis; 2, focal bridging fibrosis; 3, bridging
fibrosis with lobular distortion; and 4, cirrhosis.
HSC isolation and culture
HSCs were isolated from C57BL/6 male mice (16-18 weeks
of age) by pronase/collagenase perfusion and density centri-
fugation methods using Nycodez [31,32]. Isolated HSCs
were either placed and stored at -80°C in order to evaluate
HSC at quiescent stage, or cultured on uncoated tissue
culture dishes (1-4 × 104cells/cm2) in DMEM supple-
mented with 10% FBS and penicillin in 95% air 5% CO2
humidified atmosphere at 37°C for culture activation.
The culture activated HSCs were harvested after 7 days.
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and culture activated group.
RNA extraction and gene expression analysis by
quantitative real-time polymerase chain reaction (PCR)
Total RNA was extracted from frozen whole liver or iso-
lated HSCs using Trizol reagent (Invitrogen, Carlsbad,
CA, USA) or Qiagen mini columns (Quiagen Inc. Valencia,
CA, USA) according to the manufacturer’s protocol. RNA
samples were quantified by spectrophotometry. The RNA
integrity was assessed using agarose gel electrophoresis
and ethidium bromide staining. The RNA samples were
then diluted in RNase-free water and stored at –70°C until
use. Five micrograms of RNA were reverse-transcribed
using RNA PCR kit version 1.2 (Takara Bio Inc, Japan)
according to the manufacturer’s recommendations. Oligo-
nucleotide primers and TagMan probe for KLF10, TGFβ,
Smad 2, 3, 7, tumor necrosis factor (TNF)α, ChREBP, sterol
regulatory element binding protein (SREBP)-1c, collagen
α1(I) (Col1α(I)) and smooth muscle α-actin (αSMA) were
used with 18S as internal control. The probes were
obtained from Applied Biosystems (Perkin-Elmer/PE
Applied Biosystems, Forster City, CA, USA), purchased
as a ready-for-use form in Assays-on-Demand Gene
Expression Products. The TaqMan probes were labeled
at the 5’ end with the reporter dye FAM and minor
groove binder (MGB) nonfluorescent quencher on the
3’end. The quantitative PCR was performed in triplicate
for each sample on Step One Plus Real Time System
(Applied Biosystems). Each 20-μL reaction contained
10 uL of TaqMan Fast Universal Master Mix (Applied
Biosystems, Darmstadt, Germany), 1 uL of Gene Expres-
sion Mix and 2 uL of cDNA diluted in 7 μL RNase-free
water. The thermal cycler conditions were 20 seconds
at 95°C, 40 cycles of 5 seconds at 95°C followed by
20 seconds at 60°C. mRNA fold changes in target genes
relative to the endogenous 18S control were calculated
as suggested on previous studies [33].
Protein extraction and immunoblotting
Whole liver protein lysates were extracted using a Triton-
X 100 lysis buffer with protease inhibitors, and quantified
using the Bradford method with BSA [34]. SDS-PAGE
analysis of proteins levels was determined by means of
immunoblotting using mouse anti-Klf10 (Santa Cruz,
Santa Cruz, CA), and rabbit anti-β-actin conjugated to
HRP (Cell Signaling Technology Inc., Trask Lane Danvers,
MA). Epitope-primary antibody complexes were detected
with species-specific secondary antibodies conjugated to
HRP followed by ECL (Thermo Fisher Scientific Pierce,
Illinois). Autoradiograms of blots were scanned and
quantified using an image processor program (ImageJ
from National Institute of Health). β-actin was used as
a loading control.Measurement of liver 4-hydroxynonenal (HNE)-protein
adducts in mice liver
A quantitative OxiSelect HNE-His Adduct enzyme-linked
immunosorbent assay kit (Cell Biolabs, San Diego, CA,
USA) was used for determination of HNE-protein adducts
according to the manufacturer’s instruction. Briefly, bovine
serum albumin standards or protein extracts from the
liver tissues (10 μg/mL) were absorbed onto a 96-well
plate overnight at 4°C. After washing 100 μL diluted
anti-4-HNE-His antibody (1:1000) was added to each well
and incubated for 1 hour at room temperature, followed
by incubation with 100 μL of horseradish peroxidase-
conjugated secondary antibody (1:1000) for an hour. After
washing, 100 μL of substrate solution was added and
then the reaction was stopped by adding 100 μL of stop
solution after 10 minutes. The absorbance was measured
at 450 nm on a microplate reader. The 4-HNE-protein
adducts content in the protein samples is determined
according to a standard curve prepared from predeter-
mined 4-HNE-bovine serum albumin standards.
Statistical analysis
All the results are presented as means ± standard error
of mean (SEM). Data were analyzed by nonparametric
analysis (Kruskal-Wallis or Mann-Whitney test) or one-
way ANOVA with Tukey’s post hoc analysis. P < 0.05
was considered statistically significant. All calculations
were performed with SPSS version 15.0 software (SPSS
Inc., Chicago, IL, USA).
Results
Aging did not affect the expression of KLF10 in the liver
Since a recent study reported that aging promoted diet
induced NASH in mice [35], expression of KLF10 mRNA
in the liver was compared among the liver specimens of
mice fed with SD for 12, 24 and 48 weeks (n = 8, for
each ages). There was no statistically significant difference
in KLF10 expression by aging (P = 0.393) (Figure 1A).
Expression of TGFβ, Smad7, 2, 3, TNFα, Col1α(I) and
ChREBP mRNA were also tested at different age groups.
These genes all demonstrated no significant changes by
aging (data not shown).
Administration of HFSD induced NASH
Eight week old mice were fed with HFSD at least for
12 weeks up to 48 weeks and the mice were sacrificed at
12, 24, or 48 weeks after feeding (n = 8 for each groups)
at ZT8. Mice which were given SD for 12 weeks served
as control. Body weights and serum biochemical findings
are summarized in Table 1. Feeding HFSD for 48 weeks
resulted in increased serum cholesterol levels (P = 0.043).
Giving HFSD for 24 weeks demonstrated significantly
elevated serum ALT levels (P = 0.029) which worsened
after 48 weeks of treatment (P = 0.000 when compared
Figure 1 Changes in KLF10 and other associated gene expression in diet induced NASH. C57BL/6 mice were fed with high fat, sucrose diet
(HFSD) and sacrificed at 12, 24, or 48 weeks after the feeding. Mice that were given standard diet (SD) for 12 weeks served as control. A, KLF10
mRNA expression in the liver of SD fed mice showed no significant changes according to their age when test at the age of 12, 24, and 48 weeks
after SD feeding (P = 0.393). B, Significant up-regulation of KLF10 mRNA was observed by week 12 and thereafter when compared with the mice fed
with SD which served as control (P = 0.003). Expression of Colα(I) mRNA significantly increased at week 24 and 48 (P = 0.004) when compared with
that of mice fed with SD for 12 weeks. C, Significant increase of TGFβ mRNA was detected from week 24 and it progressed at week 48 (P = 0.001).
Downstream Smad 2, and 3 also increased as fibrosis progressed although significant increase of Smad 2 (P = 0.003) and 3 (P = 0.042) were
demonstrated as early as week 12. Inhibitory Smad7 increased from week 24 (P = 0.002). D, Expression of ChREBP which is reported to have a
protective effect on insulin resistance, decreased with HFSD feeding, although the change was not related with either the duration of HFSD feeding or
the severity of NASH (P = 0.023). Expression of a lipogenic gene, SREBP-1c showed no significant change with HFSD feeding (P = 0.167). *P < 0.05, when
compared with that of mice fed with SD. **P < 0.05 when compared with that of mice fed with HFSD for the shorter duration.
Table 1 Characterization of mice fed with HFSD†
Age diet 12 SD‡ (n = 8) 12 HFSD (n = 8) 24 HFSD (n = 8) 48 HFSD (n = 8)
Weight 25.83 ± 0.95 30.76 ± 3.32 36.77 ± 3.15 46.8 ± 2.41*
Serum glucose (mg/dL) 125.00 ± 35.60 73.80 ± 8.11 54.33 ± 3.67 116.00 ± 18.00
Serum TG¶ (mg/dL) 119.00 ± 2.65 83.20 ± 14.11 74.00 ± 7.09 124.00 ± 7.23
Serum Chol†† (mg/dL) 82.33 ± 4.07 112.80 ± 13.62 136.67 ± 27.84 158.00 ± 5.20*
Serum ALT‡‡ (IU/L) 25.00 ± 3.05 81.00 ± 15.32 123.33 ± 24.25* 393.00 ± 26.58*
Data are expressed as mean ± standard of error (SE).
†HFSD, high fat and sucrose diet.
‡SD, standard chow is considered as standard diet.
¶TG, triglyceride.
††Chol, cholesterol.
‡‡ALT, alanine aminotransferase.
*P < 0.05, when compared with mice given SD.
Results with statistical significances are shown in bold letters.
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Table 2 Nonalcoholic fatty liver disease (NAFLD) activity
score (NAS) and fibrosis score of mice fed with HFSD†
Age diet 12 SD‡
(n = 8)
12 HFSD
(n = 8)
24 HFSD
(n = 8)
48 HFSD
(n = 8)
NAS§ 0.00 ± 0.00 3.20 ± 0.49* 7.33 ± 0.33* 6.83 ± 0.31*
Fibrosis 0.00 ± 0.00 0.02 ± 0.20 2.00 ± 0.00* 2.42 ± 0.08*,**
Data are expressed as mean ± standard of error (SE).
†HFSD, high fat and sucrose diet.
‡SD, standard chow is considered as standard diet
§NAS, nonalcoholic fatty liver disease activity score, which is the summation of
the pathologic scores for steatosis, inflammation and hepatic ballooning.
*P < 0.05, when compared with mice given HFSD.
**P < 0.05, when compared with mice given HFSD for 24 weeks.
Results with statistical significances are shown in bold letters.
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week 24). Administration of HFSD induced liver inflam-
mation and fibrosis, characteristics of NASH (Figure 2A).
NAS was significantly increased from week 12 of HFSD
feeding (P = 0.012) (Table 2). On the other hands, signifi-
cant increase in fibrosis score was noticed from week 24
of HFSD feeding (P = 0.004) (Table 2).
Expression of liver KLF10 increased in HFSD induced NASH
Expression of KLF10 in the liver significantly increased
after 12 weeks of HFSD diet feeding compared with that
of the mice fed with SD for 12 weeks which served as
control (Figure 1B). However, KLF10 expression at week
48 did no show significant difference when compared
with that at week 24 (P = 0.282). Administration of HFSD
also showed increased expression of KLF10 protein that
was evident after 24 weeks of feeding (Figure 3A,B). In
accordance with histological analysis, hepatic Col1α(I)
mRNA expression increased by week 24 following the
increase of Klf-10 expression (Figure 1B).
TGFβ mRNA increased in the liver although expression of
Smad7 was not reduced in HFSD induced NASH
Since KLF10 is initially identified as a TGFβ-inducible early
gene (TIEG) and is known to act by repressing the in-
hibitory Smad 7 [36], we evaluated liver mRNA expressionFigure 2 Histological assessment of inflammation and fibrosis in diet
inflammation, existence of hepatocyte ballooning and fibrosis was performed a
evaluation of mice fed with high fat, sucrose diet (HFSD). Liver specimens were
diet (SD) for 12 weeks served as the control. B, Representative histologica
with ursodeoxycholic acid (UDCA). Mice were fed with HFSD for 24 weeks an
vehicle, and the other group was given HFSD with UDCA for another 24 weeof TGFβ, Smad7 as well as Smad2 and 3. Hepatic TGFβ
mRNA expression increased from week 24 of HFSD feed-
ing when KLF10 mRNA expression started to increase
from week 12 (Figure 1C). Smad 2 and 3, that are down-
stream mediators of TGFβ were evaluated. Although both
Smad2 and 3 started to increase from week 12 of HFSD
administration, Smad3 expression was not affected by
the length of HFSD feeding when Smad2 expression
augmented as the duration of HFSD feeding prolonged
(Figure 1C). Even with the increased KLF10 expression,
inhibitory Smad7 also increased from week 24 and
thereafter (Figure 1C).induced NASH. Histological analysis of the liver evaluating fatty change,
fter H&E (X200) and Sirus red (X100) staining. A, Representative histological
obtained at 12, 24, or 48 weeks after the feeding. Mice fed with standard
l assessment of mice fed with SD, HFSD and HFSD in combination
d divided into two groups, from which one group was given HFSD with
ks. Mice fed with SD and vehicle for 48 weeks served as the control.
Figure 3 Changes in KLF10 protein. Western blot analysis of KLF10 was performed with β-actin antibody as a loading control. Autoradiogram
of the blot was scanned and quantified using an image processor program. A representative Western blot and the result of quantitative analysis
are shown. A, A representative Western blot autoradiogram B, KLF10 protein increased after 24 weeks of high fat, sucrose diet (HFSD24) feeding
and more so after 48 weeks of feeding (HFSD48). Mice that were given standard diet is designated as SD. C, KLF10 protein which was increased
after 48 weeks of HFSD feeding, was attenuated when ursodeoxycholic acid (UDCA) was given with HFSD (HFSD/UDCA).
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KLF10 expression in HFSD induced NASH
It is reported that overexpression of ChREBP induces
KLF10 whereas KLF10 overexpression partially suppresses
ChREBP target genes in hepatocytes [27]. We were curi-
ous how ChREBP would behave when KLF10 expres-
sion increased in HFSD induced NASH. Feeding HFSD
resulted in suppressed ChREBPmRNA expression although
the reduction rate did not correlate with the duration
of HFD administration (Figure 1D). Another lipogenic
gene, SREBP-1c was tested and demonstrated no definite
difference in hepatic expression after HFSD administration
(Figure 1D).
Concurrent administration of UDCA and HFSD resulted in
decreased Colα1(I) mRNA expression that coincided with
reduction of KLF10
UDCA is reported to be beneficial in experimental NASH
[37,38]. Therefore we investigated whether adding UDCA
to HFSD would facilitate alleviation of NASH and be
accompanied by changes in KLF10 as well as other NASH
associated genes. Mice were fed with HFSD for 24 weeks
and divided into two groups. They were given either
HFSD with vehicle or HFSD with UDCA for another
24 weeks. Mice that were given SD received vehicle and
served as control. Body weights and serum biochemical
findings are summarized in Table 3. Giving HFSD resulted
in increased body weight, serum cholesterol and ALT
levels, and adding UDCA reversed the effect of HFSD.
Pathological evaluation revealed that concurrent ad-
ministration of UDCA and HFSD had decreased NAS
even though improvement in fibrosis score was notevident (Table 4) (Figure 2B). Administration of UDCA
with HFSD showed diminished Col1α(I) mRNA expres-
sion which also coincided with decreased hepatic KLF10
and TGFβ mRNA (Figure 4A). Attenuated expression
of KLF10 could also be detected on protein level after
concurrent feeding of UDCA and HFSD (Figure 3A,C).
UDCA significantly decreased the expression of NASH
associated genes
Giving UDCA with HFSD could reverse the expression
of Smad 2 and Smad3 mRNA in the liver. However,
UDCA also attenuated the expression of inhibitory Smad7
(Figure 4B). Expression of ChREBP mRNA which was
reduced by HFSD feeding was recovered by adding
UDCA to HFSD (Figure 4C).
Expression of pro-inflammatory cytokine TNFα is
reported to be increased in NASH [39]. UDCA admin-
istration alleviated increased TNFα mRNA expression
(Figure 4D) in accordance with the result of histological
analysis (Table 4) (Figure 1B).
Effect of UDCA on NASH was not associated with
decreased HNE protein adducts
Protective effect of UDCA on liver injury is frequently
reported to be associated with relieving oxidative stress
[38,40-42]. We evaluated whether beneficial effect of
UDCA on NASH in our study was associated with
decreased aldehyde-protein adduct formation, a conse-
quence of the oxidative stress [43]. However, increased
4-HNE protein adducts by feeding HFSD was not sig-
nificantly reduced by concomitant administration of
UDCA (Figure 5).
Table 3 Characterization of mice given HFSD† with or without UDCA‡
Age diet 48 SD§ (n = 8) 48 HFSD (n = 8) 48 HFSD/UDCA (n = 8)
Weight 35.33 ± 1.45 46.8 ± 2.41* 43.05 ± 1.42
Serum glucose (mg/dL) 366.00 ± 56.04 116.00 ± 18.00 132.67 ± 0.88
Serum TG¶ (mg/dL) 180.67 ± 13.96 124.00 ± 7.23 107.33 ± 28.03
Serum Chol†† (mg/dL) 89.33 ± 6.77 158.00 ± 5.20* 121.00 ± 16.44
Serum ALT‡‡ (IU/L) 70.00 ± 14.19 393.00 ± 26.58* 87.33 ± 11.57
Data are expressed as mean ± standard of error (SE).
†HFSD, high fat and sucrose diet.
‡UDCA, ursodeoxycholic acid.
§SD, standard chow is considered as standard diet.
¶TG, triglyceride.
††Chol, cholesterol.
‡‡ALT, alanine aminotransferase.
*P < 0.05, when compared with mice given SD.
Results with statistical significances are shown in bold letters.
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expression
HSCs are the major cellular component of liver fibrosis
by producing ECM and collagen [44]. The profibrogenic
capacity of HSCs is eminent when they are activated.
Since our study demonstrated that increased KLF10 co-
incided with progression of liver fibrosis, we evaluated if
KLF10 expression was associated with HSC activation.
Primarily isolated HSCs were culture activated and
expression of KLF10 mRNA was evaluated along with
αSMA, a marker for HSC activation. Primarily isolated
HSCs without culture activation served as control. Ex-
pression of αSMA was increased in activated HSCs when
it was hardly detected in quiescent cells (Figure 6A). In
accordance with αSMA, expression of KLF10 increased
in activated HSCs (Figure 6B).Discussion
A pleiotropic cytokine TGFβ is well known for its profi-
brogenic effect through HSC in the liver [44]. Role of
TGFβ signaling in progression of NASH associated fi-
brosis is also reported in several studies, making it an
attractive target for the treatment [45,46]. Moreover, a
study reported that TGFβ/Smad signaling is involved inTable 4 Effect of ursodeoxycholic acid (UDCA)
administration on diet induced nonalcoholic fatty liver
disease (NAFLD) activity score (NAS) and fibrosis score
Age diet 48 SD† (n = 8) 48 HFSD‡ (n = 8) 48 HFSD/UDCA (n = 8)
NAS§ 0.00 ± 0.00 8.17 ± 0.40* 4.00 ± 0.44*,**
Fibrosis 0.00 ± 0.00 2.42 ± 0.08* 2.07 ± 0.53*
Data are expressed as mean ± standard error (SE).
†SD, standard chow is considered as standard diet.
‡HFSD, high fat and sucrose diet.
§NAS, nonalcoholic fatty liver disease activity score, which is the summation of
the pathologic scores for steatosis, inflammation and hepatic ballooning.
*P < 0.05, when compared with mice given SD.
**P < 0.05, when compared with mice given HFSD.
Results with statistical significances are shown in bold letters.regulating insulin gene and suggested its role in the
development of insulin resistance [47,48]. Smad3 deleted
mice are protected from insulin resistance and high fat
diet induced obesity [49]. When TGFβ receptor type II
is selectively deleted in hepatocytes of mice, the mice
would be resistant to diet induced NASH and fibrosis
[50]. Although evidences suggest that blocking TGFβ
would be beneficial for NASH, targeting TGFβ at the
receptor level is probably not recommendable considering
the multi-functional role of TGFβ. Systemic mutation
of TGF-β1 is found to be lethal [51]. More studies may
be required in order to find targets that would alleviate
the adverse effects of TGFβ with minimal influence on
the critical and beneficial role of the cytokine.
KLF10 is originally named as TIEG, which would
increase about 30 minutes after TGFβ treatment and
rapidly return to the normal level within 2 hours [52].
Turnover of KLF10 and its subsequent role can be
regulated by its proteasomal degradation, and this can
modulate TGFβ/Smad-dependent transcriptional activity
[53]. KLF10 suppresses cell proliferation, induce apoptosis,
and modulate immune system [18,21,22,54]. Although
KLF10 deficient mice are reported to grow and reproduce
normally [55], these mice demonstrate defects in healing
potential [56,57], and abnormally enhanced T cell function
resulting in aggravated atherosclerosis [54]. A transcrip-
tome profiling study using the liver of KLF10 deficient mice
reveals that KLF10 has a significant role in regulating genes
that are involved in lipid and carbohydrate metabolism
[23]. ChREBP, which is also suspected to be modulated by
KLF10 [27], is a transcription factor that is observed to play
a protective role in insulin resistance although it would
aggravate simple hepatic steatosis [26]. In our study where
NASH, instead of simple steatosis without inflammation, is
induced by giving HFSD, liver expression of ChREBP
significantly decreased and its expression recovered when
NASH was alleviated by UDCA administration. Depression
of ChREBP coincided with increase of KLF10 expression
Figure 4 Decreased KLF10mRNA expression and improved NASH upon UDCA administration with HFSD. C57BL/6 mice were fed with either
standard diet (SD) or high fat, sucrose diet (HFSD) for 24 weeks upon which mice on HFSD were divided into two groups, and fed with either 20 mg/kg
UDCA diluted in 0.78% Tween-80 or 0.78% Tween-80 only. Mice fed with SD were also given 0.78% Tween-80 as vehicle. These three groups of mice
namely SD with vehicle, HFSD with vehicle and HFSD with UDCA, were fed for another 24 weeks. Total RNA was extracted from the liver. A, Expression
of Colα(I) mRNA was increased by HFSD feeding but reversed when HFSD was given in combination with UDCA (P= 0.004). KLF10 (P= 0.002) along with
TGFβ (P= 0.003) mRNA expression also reduced upon UDCA administration with HFSD. B, TGFβ downstream signaling Smad 2 (P= 0.024), and 3 (P= 0.004)
expression significantly diminished by UDCA feeding in combination with HFSD although inhibitory Smad7 (P = 0.002) also reduced when
UDCA was given. C, Expression of ChREBP mRNA was decreased by HFSD feeding but partially recovered when UDCA was given in combination with
HFSD (P = 0.007). D, Expression of inflammatory cytokine TNFα mRNA which was up-regulated by HFSD feeding, reduced by UDCA administration
(P = 0.002). *P < 0.05, when compared with that of mice fed with SD. **P < 0.05 when compared with that of mice fed with HFSD.
Figure 5 Increased 4-hydroxynonenal (HNE)-protein adducts was
not reduced by UDCA administration. C57BL/6 mice were fed with
either SD or HFSD for 24 weeks upon which mice on HFSD were
divided into two groups, and fed with either 20 mg/kg UDCA diluted
in 0.78% Tween-80 or 0.78% Tween-80 only. Mice fed with SD were
also given 0.78% Tween-80 as vehicle. A quantitative OxiSelect HNE-His
Adduct enzyme-linked immunosorbent assay kit was used for
determination of HNE-protein adducts, which is the consequence
of oxidative stress. Feeding HFSD significantly produced HNE
adducts, and this was not reduced by UDCA administration.
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expression that are signs of progressive liver fibrosis. A
study where KLF10 is overexpressed in the hepatocytes
demonstrates blunted ChREBP role in regulating carbo-
hydrate metabolism [27], and it can be speculated that
increased KLF10 along with attenuated ChREBP expression
may have some association with progression of NASH.
In addition to liver fibrosis, it is well established that
inflammation is also very important in development and
progression of NASH [30,39]. Previous reports suggest
the important role of KLF10 as a modulator of regulatory T
cell function and deleting KLF10 demonstrates enhanced
inflammatory reaction in cardiovascular system [54]. Al-
though it is observed that high fat diet induced steatosis is
accompanied by depletion of hepatic regulatory T cells
[58], association of this regulatory T cell depletion and
KLF10 has never been investigated. In our study, KLF10
up-regulation was coincided with increase in TNFα and
worsening of histologically evaluated NAS, and the precise
mechanistic role of KLF10 in inflammatory reaction of
NASH should be sought in the future, possibly through a
KLF10 deletion study.
Figure 6 Expression of KLF10 in activated hepatic stellate cells (HSC). Primarily cultured HSCs were placed on a plastic dish for 7 days in
order induced culture stimulated activation (AHSC). Quiescent HSCs (QHSC) without culture activation served as control. A, Quantification of
αSMA mRNA, a sign of HSC activation, demonstrated the increased αSMA in activated HSCs when it was hardly detected in quiescent cells. B,
Enhanced KLF10 mRNA was noticed in activated HSCs when minimal expression was visible in quiescent cells.
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early gene which would rapidly return to the normal level
within 2 hours after the stimulation. However, in the set-
ting of HFSD induced NASH or culture activated HSCs,
the insults are given repeatedly and these continuous
stimulations may have resulted in chronic activation of
KLF 10.
Although clinical trials fail to show a meaningful effect
of UDCA on alleviating NASH induced fibrosis, benefi-
cial role of UDCA has been supported by several animal
studies. These discrepancies may be explained by high
UDCA dose used in animal studies that could hardly be
achieved in humans [39]. Nevertheless, since the goal of
our study was to investigate whether improvement in
NASH would be accompanied by modulation of KLF10
expression, UDCA was used as a safe means of investiga-
tion. We observed that concurrent administration of
UDCA and HFSD reduced Col1α(I) mRNA production.
This improvement was accompanied by decreased KLF10
and TGFβ as well as recovered ChREBP expression in the
liver, suggesting that enhanced KLF10 transcription might
be related with NASH progression although the precise
cause-and-effect mechanism should be delineated by
another interventional study.
Our study revealed that activated HSCs were accom-
panied by increased KLF10 when KLF10 expression was
negligible in quiescent HSCs. This finding still cannot
explain whether KLF10 facilitates the progression of
NASH fibrosis or the consequence of the liver fibrosis.
However, it is worth noting that KLF10 expression is
enhanced in ECM producing HSC.
The beneficial effects of UDCA on NASH can be ex-
plained by its anti-inflammatory, hepatoprotective effect
as well as its role as an antioxidant [38,41,59,60]. Although
our study showed significantly decreased TNFα expression
after UDCA administration, it failed to show meaningful
decrease in 4-HNE protein adducts, which is the conse-
quence of oxidative insult. However, oxidative stress can
be evaluated by multiple means and not having decreased4-HNE protein adducts production cannot conclusively
deny UDCA’s role as an antioxidant in relieving NASH.
Our study rather suggests that UDCA takes through mul-
tiple pathways in alleviating NASH.
Conclusions
To our knowledge, this is the first study that evaluated
the expression of KLF10 in NASH and HSCs. Our study
demonstrated that KLF10 expression was significantly
increased in diet induced NASH and ECM producing
activated HSCs. We also observed that this up-regulation
of KLF10 was accompanied by increased TGFβ signaling
genes and suppressed ChREBP expression which was
known to improve insulin resistance. These observations
may suggest possible association of KLF10 in progression
of NASH. Further studies should be warranted to assess
the specific role and mechanism of KLF10 in NASH asso-
ciated liver fibrosis.
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